Mutation analysis of the negative regulator cyclin G2 in gastric cancer

African Journal of Biotechnology

Volumn 10, Issue 65, 2011, Pages 14618-14624

  Gao, Jinlan ^a   Liu, Qi ^a   Liu, Xing ^a   Zhang, Yang ^a   Wang, Shusen ^a   Luo, Yang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin G2; Gastric cancer; Mutation screen; Negative regulator

Indexed keywords

CYCLIN G2; GENOMIC DNA;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYCLIN G2 GENE; DOWN REGULATION; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH CARCINOGENESIS;

EID: 80054978363     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: 10.5897/ajb11.890     Document Type: Article

References (25)

1. Aguilar V, Annicotte JS, Escote X, Uendrell J, Langin D, Fajas L (2010). Cyclin G2 regulates adipogenesis through PPAR gamma coactivation. Endocrinology, 151(11): 5247-5254.
2. Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M, Gallagher GT, Varvares M, Cohen D, Kim D, Kent R, Donoff RB, Todd R, Yung CM, Warrington JA, Wong DT (2001). Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene, 20: 6196-6204.
3. Arachchige Don AS, Dallapiazza RF, Bennin DA, Brake T, Cowan CE, Horne MC (2006). Cyclin G2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-dependent cell cycle arrest. Exp. Cell Res. 312: 4181-4204.
4. Bates S, Rowan S, Vousden KH (1996). Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene, 13: 1103-1109.
5. 1/S phase cell cycle arrest. J. Biol. Chem. 277: 27449-27467.
6. Bogni A, Cheng C, Liu W, Yang W, Pfeffer J, Mukatira S, French D, Downing JR, Pui CH, Relling MV (2006). Genome-wide approach to identify risk factors for therapy-related myeloid leukemia. Leukemia, 20: 239-246.
7. Chen YN, Chen H, Xu Y, Zhang X, Luo Y (2008). Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance. World J. Gastroenterol. 14: 292-297.
8. Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, Kim KM, Sohn TS, Kim S (2009). Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression. J. Surg. Res. 157(2): 168-174.
9. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, Wahl AF (1997). Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J. Biol. Chem. 272: 12650-12661.
10. Horne MC, Donaldson KL, Goolsby GL, Tran D, Neubauer M, Wah AF (1996). Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J. Biol. Chem. 271: 6050-6061.
11. Hydbring P, Larsson LG (2010). Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res. 70(17): 6687-6691.
12. Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A (2003). Decreased expression of cyclin G2 is significantly linked to the malignant transformation of papillary carcinoma of the thyroid. Anticancer. Res. 23: 2335-2338.
13. Jensen MR, Audolfsson T, Keck CL, Zimonjic DB, Thorgeirsson SS (1999). Gene structure and chromosomal localization of mouse cyclin G2 (CCNG2). Gene, 230: 171-180.
14. Jia JS, Xu SR, Ma J, Ha S, Guo XN, Wang Y (2005). Expression of cyclin g2 mRNA in patients with acute leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13: 254-259.
15. Kasukabe T, Okabe-Kado J, Honma Y (2008). Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci. 99: 1693-1698.
16. Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT (2004). Cyclin G2 dysregulation in human oral cancer. Cancer Res. 64: 8980-8986.
17. Lang C, Calegari F (2010). Cdks and cyclins link G(1) length and differentiation of embryonic, neural and hamatopoietic stem cells. Cell cycle 9(10): 1893-1900.
18. Liu Q, Gao JL, Liu X, Wang SS, Luo Y (2011). Monitoring cyclindependent kinase 2 (CDK2) activity with Kinase-Glo, a luminescencebased ATP quantitative reagent. Afr. J. Biotechnol. 10(7): 1217-1220.
19. Martínez-Gac L, Marqués M, García Z, Campanero MR, Carrera AC (2004). Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol. Cell Biol. 24: 2181-2189.
20. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS (2006). Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. J. Biol. Chem. 281: 16272-16278.
21. Tian YL, Liu FR, Liu J, Jiang L, Luo Y, Zhang X (2002). Ectopic expression of cyclin G2 inhibits cell proliferation in HeLa cancer cell line. Chin. J. Cancer, 21: 577-581.
22. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ (2010). Dyregulation of cellular signaling in gastric cancer. Cancer Lett. 295(2): 144-153.
23. Xu GX, Bernaudo S, Fu GD, Lee DY, Yang BB, Peng C (2008). Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like 7. Mol. Biol. Cell 19: 4968-4979.
24. Yue LM, Daikoku T, Hou XN, Li ML, Wang HB, Nojima H, Sudhansu KD, Sanjoy KD (2005). Cyclin G1 and cyclin G2 are expressed in the periimplantation mouse uterus in a cell-specific and progesteronedependent manner: evidence for aberrant regulation with Hoxa-10 deficiency. Endocrinology, 146: 2424-2433.
25. Zandi K, Tajbakshs S, Nabipour I, Rastian Z, Yousefi F, Sharafian S, Sartari K (2010). In Vitro antitumor activity of Gracilaria corticata(a red alga) against Jurkat and molt-4 human cancer cell lines. Afr. J. Biotechnol. 9(40): 6787-6790.